Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

281. Cognitive behavioural therapy and short-term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled trial

Cognitive behavioural therapy and short-term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled trial Cognitive behavioural therapy and short-term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled trial Cognitive behavioural (...) therapy and short-term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled trial Goodyer IM, Reynolds S, Barrett B, Byford S, Dubicka B, Hill J, Holland F, Kelvin R, Midgley N, Roberts C, Senior R, Target M, Widmer B, Wilkinson P & Fonagy P Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation

2017 Health Technology Assessment (HTA) Database.

282. Accessibility and implementation in the UK NHS services of an effective depression relapse prevention programme: learning from mindfulness-based cognitive therapy through a mixed-methods study

Accessibility and implementation in the UK NHS services of an effective depression relapse prevention programme: learning from mindfulness-based cognitive therapy through a mixed-methods study Accessibility and implementation in the UK NHS services of an effective depression relapse prevention programme: learning from mindfulness-based cognitive therapy through a mixed-methods study Accessibility and implementation in the UK NHS services of an effective depression relapse prevention programme (...) and implementation in the UK NHS services of an effective depression relapse prevention programme: learning from mindfulness-based cognitive therapy through a mixed-methods study. Health Services and Delivery Research 2017; 5(14) Authors' objectives To describe the existing provision of mindfulness-based cognitive therapy (MBCT) in the UK NHS, develop an understanding of the perceived costs and benefits of MBCT implementation, and explore the barriers and critical success factors for enhanced accessibility. We

2017 Health Technology Assessment (HTA) Database.

283. Conditional Human Immunodeficiency Virus Transactivator of Transcription Protein Expression Induces Depression-like Effects and Oxidative Stress Full Text available with Trip Pro

Conditional Human Immunodeficiency Virus Transactivator of Transcription Protein Expression Induces Depression-like Effects and Oxidative Stress The prevalence of major depression in those with HIV/AIDS is substantially higher than in the general population. Mechanisms underlying this comorbidity are poorly understood. HIV-transactivator of transcription (Tat) protein, produced and excreted by HIV, could be involved. We determined whether conditional Tat protein expression in mice is sufficient (...) to induce depression-like behaviors and oxidative stress. Further, as oxidative stress is associated with depression, we determined whether decreasing or increasing oxidative stress by administering methylsulfonylmethane (MSM) or diethylmaleate (DEM), respectively, altered depression-like behavior.GT-tg bigenic mice received intraperitoneal saline or doxycycline (Dox, 25-100 mg/kg/day) to induce Tat expression. G-tg mice, which do not express Tat protein, also received Dox. Depression-like behavior

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

284. Primary care Screening Questionnaire for Depression: reliability and validity of a new four-item tool Full Text available with Trip Pro

Primary care Screening Questionnaire for Depression: reliability and validity of a new four-item tool Unidentified depression in primary care is a public health concern, globally. There is a need for brief, valid and easily administered tools in primary care.To estimate reliability and validity of the newly developed Primary care Screening Questionnaire for Depression (PSQ4D), a four-item tool, with 'yes' or 'no' options.PSQ4D was administered verbally (time required, <1 min) by primary care (...) predictive value was 0.98, positive likelihood ratio was 7.4 and negative likelihood ratio was 0.05.When physician administered, PSQ4D has good reliability. At a cut-off score of ≥2, it has high sensitivity and specificity to identify depressive disorder in primary care.None.© The Royal College of Psychiatrists 2017. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) license.

2017 BJPsych open

285. Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study Full Text available with Trip Pro

Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study Preclinical and postmortem studies have implicated the metabotropic glutamate receptor 5 (mGluR5) in the pathophysiology of major depressive disorder (MDD). The goal of the present study was to determine the role of mGluR5 in a large group of individuals with MDD compared to healthy controls (HC) in vivo with [18F]FPEB and positron emission tomography (PET). Furthermore, we (...) relative to creatine (Cr).No significant between-group differences were observed in mGluR5 VT or DVR. Compared to HC, individuals with MDD had higher ACC glutamate, glutamine, and Glx levels. Importantly, the ACC mGluR5 DVR negatively correlated with glutamate/Cr and Glx/Cr levels.In this novel in vivo examination, we show an inverse relationship between mGluR5 availability and glutamate levels. These data highlight the need to further investigate the role of glutamatergic system in depression.

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

286. Depression, antidepressants and driving safety Full Text available with Trip Pro

Depression, antidepressants and driving safety The purpose of this study was to review to review the reported associations of depression and antidepressants with motor vehicle crashes.A literature search for material published in the English language between January, 1995, and October, 2015, in bibliographic databases was combined with a search for other relevant material referenced in the retrieved articles.Retrieved articles were systematically reviewed for inclusion criteria: 19 (...) epidemiological studies (17 case-control and 2 cohort studies) fulfilled the inclusion criteria by estimating the crash risk associated with depression and/or psychotropic medications in naturalistic settings.The estimates of the odds ratio (OR) of crash involvement associated with depression ranged from 1.78 to 3.99. All classes of antidepressants were reported to have side effects with the potential to affect driving safety. The majority of studies of antidepressant effects on driving reported an elevated

2017 Injury epidemiology

287. Association of Suicidality and Depression With 5alpha-Reductase Inhibitors Full Text available with Trip Pro

Association of Suicidality and Depression With 5alpha-Reductase Inhibitors There have been concerns raised by patients and regulatory agencies regarding serious psychiatric adverse effects associated with 5α-reductase inhibitors.To determine if there is an increased risk of suicide, self-harm, or depression among older men starting a 5α-reductase inhibitor for prostatic enlargement.A population-based, retrospective, matched cohort study using linked administrative data for 93 197 men ages 66 (...) self-harm and depression.Men who used 5α-reductase inhibitors were not at a significantly increased risk of suicide (HR, 0.88; 95% CI, 0.53-1.45). Risk of self-harm was significantly increased during the initial 18 months after 5α-reductase inhibitor initiation (HR, 1.88; 95% CI, 1.34-2.64), but not thereafter. Incident depression risk was elevated during the initial 18 months after 5α-reductase inhibitor initiation (HR, 1.94; 95% CI, 1.73-2.16), and continued to be elevated, but to a lesser degree

2017 EvidenceUpdates

288. Accessibility and implementation in the UK NHS services of an effective depression relapse prevention programme: learning from mindfulness-based cognitive therapy through a mixed-methods study Full Text available with Trip Pro

Accessibility and implementation in the UK NHS services of an effective depression relapse prevention programme: learning from mindfulness-based cognitive therapy through a mixed-methods study Accessibility and implementation in the UK NHS services of an effective depression relapse prevention programme: learning from mindfulness-based cognitive therapy through a mixed-methods study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page (...) not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Access to mindfulness-based cognitive therapy for preventing depression relapse remains patchy across the UK, but is improving thanks to individuals who champion local implementation, often over many years. {{author}} {{($index

2017 NIHR HTA programme

289. Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study) Full Text available with Trip Pro

Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study) Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study) Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested

2017 NIHR HTA programme

290. Depression Risk in Patients with Rheumatoid Arthritis in the United Kingdom Full Text available with Trip Pro

Depression Risk in Patients with Rheumatoid Arthritis in the United Kingdom Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases. The goal of this study was to analyze the risk of depression in patients diagnosed with RA and treated by general practitioners in the UK.The present study included patients first diagnosed with RA between 2000 and 2014 (index date). Individuals were excluded if they had also been diagnosed with depression or if they had received therapy (...) for depression at or prior to the index date. The primary outcome measure was the rate of patients with depression (ICD 10: F32, 33) within 5 years of the RA diagnosis. Demographic data included gender and age. Furthermore, a revised version of the Charlson comorbidity index was used as a generic marker of comorbidity.A total of 4187 patients were included in the study. After 5 years of follow-up, 23.7% of men and 36.5% of women had developed depression (log rank p value <0.001). Women were more likely

2017 Rheumatology and therapy

291. Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations. Full Text available with Trip Pro

Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations. The co-occurrence of health burdens in transitioning populations, particularly in specific socioeconomic and cultural contexts, calls for conceptual frameworks to improve understanding of risk factors, so as to better design and implement prevention and intervention programmes to address comorbidities. The concept of a syndemic, developed by medical anthropologists, provides such a framework (...) in low-income and middle-income countries. We employ diabetes as an exemplar and discuss its comorbidity with HIV in Kenya, tuberculosis in India, and depression in South Africa. Using a model of syndemics that addresses transactional pathophysiology, socioeconomic conditions, health system structures, and cultural context, we illustrate the different syndemics across these countries and the potential benefit of syndemic care to patients. We conclude with recommendations for research and systems

2017 Lancet

292. Orbitofrontal cortex activity and connectivity predict future depression symptoms in adolescence Full Text available with Trip Pro

Orbitofrontal cortex activity and connectivity predict future depression symptoms in adolescence Major depressive disorder is a leading cause of disability worldwide; however, little is known about pathological mechanisms involved in its development. Research in adolescent depression has focused on reward sensitivity and striatal mechanisms implementing it. The contribution of loss sensitivity to future depression, as well as the orbitofrontal cortex (OFC) mechanisms critical for processing (...) losses and rewards, remain unexplored. Furthermore, it is unclear whether OFC functioning interacts with familial history in predicting future depression.In this longitudinal study we recorded functional magnetic resonance imaging (fMRI) data while 229 adolescent females with or without parental history of depression completed a monetary gambling task. We examined if OFC blood-oxygen-level-dependent (BOLD) response and functional connectivity during loss and win feedback was associated

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

293. Effect of Collaborative Care vs Usual Care on Depressive Symptoms in Older Adults With Subthreshold Depression: The CASPER Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Collaborative Care vs Usual Care on Depressive Symptoms in Older Adults With Subthreshold Depression: The CASPER Randomized Clinical Trial. There is little evidence to guide management of depressive symptoms in older people.To evaluate whether a collaborative care intervention can reduce depressive symptoms and prevent more severe depression in older people.Randomized clinical trial conducted from May 24, 2011, to November 14, 2014, in 32 primary care centers in the United Kingdom (...) among 705 participants aged 65 years or older with Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) subthreshold depression; participants were followed up for 12 months.Collaborative care (n=344) was coordinated by a case manager who assessed functional impairments relating to mood symptoms. Participants were offered behavioral activation and completed an average of 6 weekly sessions. The control group received usual primary care (n=361).The primary outcome was self-reported

2017 JAMA Controlled trial quality: predicted high

294. Which SSRIs most effectively treat depression in adolescents?

Which SSRIs most effectively treat depression in adolescents? Which SSRIs most effectively treat depression in adolescents? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Which SSRIs most effectively treat depression in adolescents? View/ Open Date 2016-09 Format Metadata Abstract Q: Which SSRIs most effectively treat (...) depression in adolescents? Evidence-based answer: We don' t know which selective serotonin reuptake inhibitors (SSRIs) are the most effective and safe because no studies have compared these antidepressants with each other. Three SSRI antidepressant medications--fluoxetine, sertraline, and escitalopram--produce modest improvements (about 5% to 10%) in standardized depression scores without a significant increase in the risk of suicide-related outcomes (suicidal behavior or ideation) in adolescent patients

2017 Clinical Inquiries

295. Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines

Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Testosterone for Depression, PTSD, or Fibromyalgia: Clinical Effectiveness and Guidelines Published on: February 9, 2017 Project Number: RA0892-000 Product Line: Research Type: Drug Report (...) Type: Reference List Result type: Report Question What is the clinical effectiveness of testosterone for patients with depression? What is the clinical effectiveness of testosterone for patients with post-traumatic stress disorder? What is the clinical effectiveness of testosterone for patients with fibromyalgia? What are the evidence-based guidelines for the use of testosterone for patients with depression, PTSD, or fibromyalgia? Key Message Two systematic reviews, two randomized controlled trials

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

296. Human Growth Hormone for Depression, Post-Traumatic Stress Disorder, or Fibromyalgia: Clinical Effectiveness and Guidelines

Human Growth Hormone for Depression, Post-Traumatic Stress Disorder, or Fibromyalgia: Clinical Effectiveness and Guidelines Human Growth Hormone for Depression, Post-Traumatic Stress Disorder, or Fibromyalgia: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Human Growth Hormone for Depression, Post-Traumatic Stress Disorder, or Fibromyalgia: Clinical Effectiveness and Guidelines Human Growth Hormone for Depression, Post-Traumatic Stress Disorder, or Fibromyalgia (...) : Clinical Effectiveness and Guidelines Published on: February 8, 2017 Project Number: RA0891-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness of human growth hormone for patients with depression? What is the clinical effectiveness of human growth hormone for patients with post-traumatic stress disorder? What is the clinical effectiveness of human growth hormone for patients with fibromyalgia? What are the evidence-based

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

297. Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review Full Text available with Trip Pro

Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review An increasing number of model-based studies that evaluate the cost effectiveness of treatments for depression are being published. These studies have different characteristics and use different simulation methods.We aimed to systematically review model-based studies evaluating the cost effectiveness of treatments for depression and examine which modelling technique is most appropriate for simulating (...) scored positively in four of the 11 criteria, CMMs in five, ISMs in six, and DES models in seven.There were substantial methodological differences between the studies. Since the individual history of each patient is important for the prognosis of depression, DES and ISM simulation methods may be more appropriate than the others for a pragmatic representation of the course of depression. However, direct comparisons between the available modelling techniques are necessary to yield firm conclusions.

2017 PharmacoEconomics open

298. Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T Full Text available with Trip Pro

Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T Examining neurometabolic abnormalities in critical brain areas in schizophrenia and major depressive disorder (MDD) may help guide future pharmacological interventions including glutamate-modulating treatments.To measure metabolite concentrations within the anterior cingulate cortex (ACC) and thalamus of people with schizophrenia and people with MDD.Spectra were acquired from 16

2017 BJPsych open

299. Low frequency right transcranial magnetic stimulation for major depressive disorder

Low frequency right transcranial magnetic stimulation for major depressive disorder Low frequency right transcranial magnetic stimulation for major depressive disorder Low frequency right transcranial magnetic stimulation for major depressive disorder HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Low frequency right transcranial (...) magnetic stimulation for major depressive disorder. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' objectives Major depressive disorder (MDD) is a leading cause of disability in the United States and in other developed countries. Approximately one-third of patients with nonpsychotic MDD may be treatmentresistant, based on failures of at least 2 trials of antidepressants. Description of Technology: Low frequency repetitive transcranial magnetic stimulation (LFrTMS

2017 Health Technology Assessment (HTA) Database.

300. High-frequency left repetitive transcranial magnetic stimulation for treatment-resistant major depressive disorder

High-frequency left repetitive transcranial magnetic stimulation for treatment-resistant major depressive disorder High-frequency left repetitive transcranial magnetic stimulation for treatment-resistant major depressive disorder High-frequency left repetitive transcranial magnetic stimulation for treatment-resistant major depressive disorder HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation HAYES, Inc.. High-frequency left repetitive transcranial magnetic stimulation for treatment-resistant major depressive disorder . Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' objectives Repetitive high-frequency left transcranial magnetic stimulation (HFL-rTMS) is a noninvasive technique that may serve as an alternative intervention for treatment-resistant depression (TRD). Brief repetitive pulses of magnetic energy are applied to the scalp

2017 Health Technology Assessment (HTA) Database.